Shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) recorded -4.54% loss during trading session on December 6th, 2018. The script traded as low as $4.44 and last traded at $4.63. 4.09 million shares changed exchanged hands during trading, a drop of -41.97% from the 30-day average session volume of 2.88M shares. The firm had previously closed at $4.85. The company has $236.46M outstanding shares, price-to-earnings-growth ratio of 72.50 and a beta of 1.33. The company has a RSI of 39.48, ATR of 0.31 and a volatility of 5.41% this week. TXMD has a 52 week low price of $4.30 and a 52 week high price of $7.66.
Investors have identified the tech company TherapeuticsMD, Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around 1.09B, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
TherapeuticsMD, Inc. (TXMD) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For TXMD, the company has in raw cash 190 million on their books with 29.28 million currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on an incline. In terms of their assets, the company currently has 0 total, with 0 as their total liabilities. This figure have given the company a good sense of viability under numerous contexts.
TXMD were able to record 0 as free cash flow during the third quarter of the year, this saw their quarterly net cash flow reduce by 0. In cash movements, the company had a total of 0 as operating cash flow.
Potential earnings growth for TherapeuticsMD, Inc. (TXMD)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the third quarter of the year, TherapeuticsMD, Inc. recorded a total of 3.47 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with -0.27% coming in sequential stages and their sales for the third quarter reducing by -0.08%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 699000 trying to sell their products during the last quarter, with the result yielding a gross income of 2.77 million. This allows shareholders to hold on to 236.46M with the revenue now reading -160 cents per share.
Is the stock of TXMD attractive?
Having a look at the company’s valuation, the company is expected to record -0.33 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on TXMD sounds very interesting.
In related news, President/Secretary Milligan John C.K. IV sold 129,000 shares of the company’s stock in a transaction that recorded on December 6th, 2018. The sale was performed at an average price of 4.57, for a total value of 589,530. As the sale deal closes, the President/Secretary Milligan John C.K. IV now sold 129,000 shares of the company’s stock, valued at 642,162. Also, Director Bernick Brian sold 91,400 shares of the company’s stock in a deal that was recorded on December 3rd, 2018. The shares were sold at an average price of 5.18 per share, with a total market value of 6,557,371. Following this completion of acquisition, the Director now holds 91,400 shares of the company’s stock, valued at 453,344. In the last 6 months, insiders have changed their ownership in shares of company stock by 8.50%.
3 out of 8 analysts covering the stock have rated it a Buy, while 0 have maintained a Hold recommendation on TherapeuticsMD, Inc. stock. 0 analysts has assigned a Sell rating on the TXMD stock. The 12-month mean consensus price target for the company’s shares has been set at $16.00.